Futura Medical PLC
FUM
Company Profile
Business description
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction (commercially available in multiple markets), Eroxon Intense (a new line extension in development) and WSD4000 which is in-development female sexual health portfolio. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union followed by USA and rest of the world.
Contact
40 Occam Road
Surrey Technology Centre
GuildfordSurreyGU2 7YG
GBRT: +44 1483685670
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
10
Stocks News & Analysis
stocks
CBA earnings: Business lending powers on, but costs and credit bear watching
Our view after the bank reports first quarter earnings.
stocks
Apple earnings review: Revenue beats estimates as memory crunch threatens margins
Apple shares are trading at record highs after posting solid results.
stocks
Nvidia: Cutting our fair value estimate by 19% given the firm’s CEO transition and turmoil
We’re reducing our long-term revenue estimates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.50 | 69.70 | -0.75% |
| CAC 40 | 8,368.91 | 7.55 | 0.09% |
| DAX 40 | 26,749.95 | 21.93 | -0.08% |
| Dow JONES (US) | 52,266.29 | 30.80 | -0.06% |
| FTSE 100 | 10,902.56 | 39.47 | 0.36% |
| HKSE | 23,637.60 | 370.95 | -1.55% |
| NASDAQ | 25,080.31 | 285.78 | -1.13% |
| Nikkei 225 | 61,142.35 | 322.99 | 0.53% |
| NZX 50 Index | 14,173.68 | 85.55 | -0.60% |
| S&P 500 | 7,543.17 | 49.23 | -0.65% |
| S&P/ASX 200 | 9,082.20 | 64.60 | -0.71% |
| SSE Composite Index | 3,634.35 | 21.48 | -0.59% |